KB
Therapeutic Areas
Pliant Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bexotegrast (PLN-74809) | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2b |
| PLN-101095 | Advanced Solid Tumors | Phase 1 |
| PLN-101325 | Undisclosed Fibrotic Indication | Preclinical |
| Muscular Dystrophy Program | Muscular Dystrophy | Discovery |
Leadership Team at Pliant Therapeutics
ÉL
Éric Lefebvre, M.D.
Chief Executive Officer
KC
Keith Cummings, M.D.
Chief Financial Officer
BC
Bernard Coulie, M.D., Ph.D.
President and Chief Executive Officer
HH
Hans Hull, M.Sc.
Chief Commercial Officer
ÉL
Éric Lefebvre, M.D.
Chief Medical Officer
JP
John P. McLaughlin
Chief Business Officer
X(
Xiaokui (Kevin) Zhang, Ph.D.
Chief Scientific Officer
LC
Lily Cheung, Ph.D.
Senior Vice President, Regulatory Affairs & Quality Assurance
RJ
Robert J. Benschop, Ph.D.
Senior Vice President, Research & Non-Clinical Development
JG
John G. M. Lee, J.D.
Senior Vice President, General Counsel & Corporate Secretary